← All trials
NCT07284290
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2026
- Primary completion
- Nov 30, 2029
- Completion date
- Nov 30, 2029
- First posted
- Dec 16, 2025
- Last posted
- Dec 16, 2025
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Virginia Commonwealth UniversityLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Virginia Commonwealth UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.